APONTIS PHARMA Aktie
WKN DE: A3CMGM / ISIN: DE000A3CMGM5
08.11.2023 20:00:27
|
EQS-Adhoc: APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program
EQS-Ad-hoc: APONTIS PHARMA AG / Key word(s): Strategic Company Decision/Restructure of Company Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014 Monheim am Rhein, 8 November 2023. APONTIS PHARMA AG („Company“, Ticker APPH / ISIN DE000A3CMGM5) today based on the nine-month figures of the current financial year announces a new forecast for 2023. Accordingly, the Company expects revenues of EUR 36.1 million and EBITDA before restructuring expenses of EUR -8.6 million in the 2023 financial year. In order to return to a profitable growth path, the Company has also adopted the announced program to increase operational performance and efficiency and presented it to the works council. The objective is to achieve significant savings by reducing personnel while at the same time increasing the effectiveness of sales and marketing. The number of jobs to be reduced is currently being negotiated with the works council. For a full financial year, savings of between EUR 6.0 million and EUR 7.0 million are expected. The necessary restructuring expenses are estimated to total between EUR 5.0 million and EUR 8.0 million. Investor Relations CROSS ALLIANCE communication GmbH End of Inside Information
08-Nov-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | APONTIS PHARMA AG |
Alfred-Nobel-Str. 10 | |
40789 Monheim | |
Germany | |
E-mail: | ir@apontis-pharma.de |
Internet: | https://apontis-pharma.de/ |
ISIN: | DE000A3CMGM5 |
WKN: | A3CMGM |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1768127 |
End of Announcement | EQS News Service |
|
1768127 08-Nov-2023 CET/CEST

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu APONTIS PHARMAmehr Nachrichten
20.08.25 |
EQS-News: APONTIS PHARMA: Changes in the management board (EQS Group) | |
20.08.25 |
EQS-News: APONTIS PHARMA: Veränderungen im Vorstand (EQS Group) | |
13.06.25 |
EQS-Adhoc: APONTIS PHARMA AG: Merger Squeeze-out Cash Compensation Determined at EUR 10.40 (EQS Group) | |
13.06.25 |
EQS-Adhoc: APONTIS PHARMA AG: Barabfindung im Rahmen des verschmelzungsrechtlichen Squeeze-Outs auf EUR 10,40 festgelegt (EQS Group) | |
15.05.25 |
EQS-News: APONTIS PHARMA veröffentlicht Ergebnisse des ersten Quartals 2025 und bestätigt Prognose 2025 (EQS Group) | |
15.05.25 |
EQS-News: APONTIS PHARMA publishes results for the first quarter of 2025 and confirms forecast for 2025 (EQS Group) |
Analysen zu APONTIS PHARMAmehr Analysen
Aktien in diesem Artikel
APONTIS PHARMA | 10,90 | 0,46% |
|